A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection.
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2019
At a glance
- Drugs VE 303 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms CONSORTIUM
- Sponsors Vedanta Biosciences
- 12 Dec 2018 Status changed from planning to recruiting, according to a PureTech Health media release.
- 04 Oct 2018 According to a PureTech Health media release, this trial is expected to begin in the fourth quarter of 2018.
- 12 Dec 2017 New trial record